What is Mexidol?
Mexidol (emoxypine succinate) is the succinic acid salt of emoxypine, 2-ethyl-6-methyl-3-hydroxypyridine, a synthetic 3-hydroxypyridine that a 2024 review describes as a derivative of vitamin B6. The same review lists emoxypine succinate as a registered drug in Russia and Ukraine under trade names including Mexidol, Mexicor and Armadin Long (Jędrejko et al., 2024), and a 2026 registry analysis found no registration for it in the United States, the United Kingdom or the European Union (Alexandrova et al., 2026).
The material Disguised Alpha supplies is not that medicine: it is emoxypine succinate in 125mg capsules for laboratory research use only. Nothing on this page is guidance for use in people.
Mexidol reference data
| Property | Value |
|---|---|
| Name | Mexidol (emoxypine succinate) |
| Also called | Emoxypine succinate, ethylmethylhydroxypyridine succinate, methylethylpiridinol succinate, 2-ethyl-6-methyl-3-hydroxypyridine succinate, Mexicor (PubChem CID 122298) |
| Structure | 1:1 salt of emoxypine (2-ethyl-6-methylpyridin-3-ol, PubChem CID 114681) with succinic (butanedioic) acid: a pyridine ring with a 3-hydroxyl, a 2-ethyl and a 6-methyl group |
| Compound class | 3-hydroxypyridine derivative (succinate salt), studied as an antioxidant |
| Molecular formula | C₁₂H₁₇NO₅ (succinate); C₈H₁₁NO (emoxypine base) |
| Molecular weight | 255.27 g/mol (succinate); 137.18 g/mol (emoxypine base) |
| Form | Capsules, 125mg per capsule, 60 capsules per bottle (7,500mg per bottle) |
| Testing | Third-party tested, with the certificate for each lot published on the product page and in the COA portal |
Formula, molecular weight, capsule format, strength and storage are from the Mexidol product page. PubChem CID 122298 lists the same formula and weight and is the source of the aliases and structure; CID 114681 gives the emoxypine base figures. The product page lists 125mg of emoxypine succinate per capsule, and the base is about 54 percent of the succinate by weight. For quantitative work, use the measured content per capsule on your lot's certificate.
See it beside the other compounds on this site in the peptide molecular weight reference table.
What the research covers
Published work on Mexidol falls into five areas. Each summary below states the model used. Most of the literature is in Russian, and all trials summarized here are Russian-led.
Antioxidant and radical-scavenging chemistry
In three chemiluminescent oxidation systems, one of them a suspension of phospholipid liposomes, Mexidol, emoxypine hydrochloride and the related 3-hydroxypyridine proxipin bound ferrous iron and scavenged reactive oxygen species or luminol radicals, with Mexidol the most active (Klebanov et al., 2001). An independent density functional theory study from Vietnam and Australia predicted moderate hydroperoxyl radical scavenging and copper(II) chelation that blocks copper reduction by ascorbate, making copper binding its main predicted route against hydroxyl radicals (Hoa et al., 2022). Models: cell-free assays and computation.
Membranes and mitochondria
Young and old rats given water-soluble 2-ethyl-6-methyl-3-hydroxypyridine over a long course showed faster calcium transport into sarcoplasmic reticulum vesicles from heart and skeletal muscle (Kagan et al., 1986). In young and aging male rats, 20-day intraperitoneal courses at 40 and 100 mg/kg raised cortical levels of the succinate receptor SUCNR1 and of mitochondrial biogenesis markers such as PGC-1α, NRF1 and TFAM, more at the higher amount (Kirova et al., 2020). Models: rat muscle membranes and rat cortex.
Rodent ischemia and neuroprotection models
In rats with transient middle cerebral artery occlusion, Mexidol at 100 mg/kg intraperitoneally, from 6 hours after surgery and then daily for 6 days, reduced infarct volume by 30 percent, against 60 percent for the comparator GK-2, but did not reduce the limb placement deficit (Povarnina et al., 2017).
After photothrombosis in the rat prefrontal cortex, a 7-day course at 100 mg/kg, like nasal Semax, was associated with preserved neuron numbers and PGC-1α expression in the penumbra (Shakova et al., 2021). Outside Russia, an Indian group reported lower brain iron, oxidative stress and inflammatory markers and changed novel tank and Y-maze behavior in iron-overloaded zebrafish exposed to emoxypine succinate (Bagwe Parab and Kaur, 2025). Models: rats and zebrafish.
Anxiety-related behavior in rodents
In BALB/c and C57BL/6 mice tested in the open field, elevated plus maze and passive avoidance, Mexidol given once at 100 mg/kg intraperitoneally had a selective anxiolytic-like effect in BALB/c mice, a strain with a passive response to emotional stress, and no sedative effect in C57BL/6 mice (Kravtsova et al., 2004).
In rats given emoxypine hydrochloride or Mexidol three times, both produced anxiolytic-like and risk behavior in the elevated plus maze, close to amitriptyline; the hydrochloride, with no succinate, was stronger, and the authors linked the weaker Mexidol effect to its succinate (Volchegorskii et al., 2015). Models: mice and rats.
Clinical trials and the evidence base
The three multicenter trials below were randomized, double-blind and placebo-controlled, and were published in Russian. In EPICA, 150 adults aged 40 to 79 with hemispheric ischemic stroke received Mexidol or placebo, intravenously for 10 days and then orally for 8 weeks; the Mexidol group ended with lower modified Rankin (p=0.04) and NIHSS (p=0.035) scores, with no significant difference in side-effect frequency (Stakhovskaya et al., 2017).
In MEMO, 318 people aged 40 to 90 with chronic brain ischemia, in Russia and Uzbekistan, received a 14-day intravenous course and then 60 days of tablets, or placebo; the primary endpoint, change in MoCA score, favored Mexidol (p<0.000001), and adverse event profiles were reported as comparable (Fedin et al., 2021).
In MIR, 304 people with recent ischemic stroke at sites in Russia, Uzbekistan and Kazakhstan received a similar sequence or placebo alongside standard care. The Mexidol group showed larger changes in modified Rankin (p=0.003), NIHSS (p<0.001) and Rivermead Mobility Index (p=0.014) scores but only a trend on MoCA, and adverse events occurred in 23 percent of each group (Shamalov et al., 2025).
A 2023 meta-analysis pooled 11 stroke studies, all reported in Russian and only 2 of them randomized. It found lower NIHSS and modified Rankin scores than in comparison groups but marked heterogeneity, and said the evidence needs further examination (Voznyuk et al., 2023). PubMed indexes no randomized trial from outside Russia and other former Soviet states, so independent replication is limited. Models: human trials and a meta-analysis.
Key studies
- Klebanov GI, et al. "[Antioxidant properties of 3-oxypyridine analogues: mexidol, emoxipin, proxipin]." Vopr Med Khim. 2001. PMID 11558311. Cell-free chemiluminescence: iron binding and radical scavenging.
- Kirova YI, et al. "[The effect of Mexidol on cerebral mitochondriogenesis at a young age and during aging]." Zh Nevrol Psikhiatr Im S S Korsakova. 2020. PMID 32105271. DOI 10.17116/jnevro202012001162. Young and aging rats: SUCNR1 and mitochondrial biogenesis markers.
- Povarnina PY, et al. "Comparison of the Pharmacological Effects of Dimeric Dipeptide Nerve Growth Factor Mimetic GK-2 and Mexidol on the Model of Ischemic Stroke in Rats." Bull Exp Biol Med. 2017. PMID 29181667. DOI 10.1007/s10517-017-3951-3. Rat stroke model: smaller infarcts, limb placement unchanged.
- Volchegorskii IA, et al. "Comparative analysis of the anxiolytic effects of 3-hydroxypyridine and succinic acid derivatives." Bull Exp Biol Med. 2015. PMID 25894772. DOI 10.1007/s10517-015-2855-3. Rat elevated plus maze: emoxypine hydrochloride compared with Mexidol.
- Shamalov NA, et al. "[Results of the international multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of the sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (MIR)]." Zh Nevrol Psikhiatr Im S S Korsakova. 2025. PMID 40898634. DOI 10.17116/jnevro202512508240. 304 adults after ischemic stroke.
Handling and storage of Mexidol capsules
General laboratory practice for this material:
- Store the sealed capsules at 15 to 25°C in the original sealed container, away from moisture and direct light (storage guidance on the product page).
- Capsules ship in a sealed plastic or glass bottle or a resealable pouch, depending on the batch; close it fully after each opening.
- Record the lot number and keep its certificate with your notes. The certificate reports HPLC purity and measured content per capsule, which can differ from the 125mg label figure.
- For identity checks, compare analytical data with C₁₂H₁₇NO₅ and 255.27 g/mol for the succinate, or C₈H₁₁NO and 137.18 g/mol for emoxypine base.
Frequently asked questions
What is Mexidol?
Mexidol is emoxypine succinate, the 1:1 salt of 2-ethyl-6-methyl-3-hydroxypyridine with succinic acid (PubChem CID 122298), registered as a drug in Russia and Ukraine (Jędrejko et al., 2024).
What is emoxypine, and is it the same as emoxypine succinate?
Emoxypine is the free base, 2-ethyl-6-methyl-3-hydroxypyridine (PubChem CID 114681; 137.18 g/mol); the succinate weighs 255.27 g/mol. Russian papers also test emoxypine hydrochloride (CID 128852), called emoxipin there, and the two salts behaved differently in rats (Volchegorskii et al., 2015), so check which one a study used.
Is Mexidol approved by the FDA?
No. The FDA's Drugs@FDA database lists no product containing emoxypine or its succinate, and the European Medicines Agency's medicines database has no entry for it (both searched October 2026). A 2026 registry analysis also found no US, UK or EU registration (Alexandrova et al., 2026).
Has Mexidol been tested in people?
Yes, as research history, in Russian-led randomized, placebo-controlled trials in ischemic stroke (Shamalov et al., 2025) and chronic brain ischemia (Fedin et al., 2021). A 2023 meta-analysis called the stroke evidence heterogeneous (Voznyuk et al., 2023), and PubMed lists no trial from outside Russia and other former Soviet states.
Is Mexidol on the WADA Prohibited List?
No. The World Anti-Doping Agency's 2026 Prohibited List and Monitoring Program do not name emoxypine or Mexidol. A 2024 anti-doping review noted that it is not included in drug testing and argued that it could merit consideration for the list because its effects resemble those of meldonium and trimetazidine, which the list prohibits as metabolic modulators (class S4.4) (Jędrejko et al., 2024).
How should Mexidol capsules be stored?
Keep them sealed in the original container at 15 to 25°C, away from moisture and direct light, as listed on the product page.
Where can researchers buy Mexidol?
Disguised Alpha sells emoxypine succinate for laboratory research as 125mg capsules, 60 per bottle, third-party tested with the certificate for each lot published on the product page: Mexidol (Emoxypine Succinate).
Related compounds and guides
- Semax research guide
- Selank research guide
- Adamax research guide
- Phenibut research guide
- Glutathione research guide
- NAD+ research guide
- COA portal: every published certificate, by lot
This product is for research use only. It has not been evaluated for safety or effectiveness in humans. Not for human consumption. All products are intended for laboratory research purposes only.